BridgeBio, Helsinn Partner Again After Truseltiq Success

Deal Snapshot: The two firms will seek to co-develop and co-commercialize targeted small molecule cancer therapies that they identify at the preclinical stage.

Businessman Success. A businessman launching upwards, paperwork flying everywhere!
BridgeBio, Helsinn hope to build on their quick success with cancer drug Truseltiq

More from Deals

More from Business